Literature DB >> 17552123

Amebic liver abscess in HIV-infected patients, Republic of Korea.

Wan Beom Park, Pyoeng Gyun Choe, Jae Hyun Jo, Sung-Han Kim, Ji Hwan Bang, Hong Bin Kim, Nam Joong Kim, Myoung-don Oh, Kang Won Choe.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17552123      PMCID: PMC2725887          DOI: 10.3201/eid1303.060894

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Amebic liver abscess (ALA) is the most common extraintestinal complication of amebic infection. Although loss of cellular immunity is thought to play a role in infection by the pathogen, whether HIV infection is also a risk factor for invasive amebiasis is controversial (–). ALA in HIV-infected patients has not been well characterized, although several case series have been reported (,). We report the role of HIV infection status in ALA in an area where ALA is not endemic and the clinical features of ALA in HIV-infected patients. All patients with ALA at Seoul National University Hospital (SNUH) from January 1990 through December 2005 were identified; some have been previously reported (). SNUH is a 1,600-bed, university-affiliated teaching hospital and the largest referral center for HIV/AIDS in the Republic of Korea. The diagnostic criteria for ALA were radiologic evidence of intrahepatic abscess, trophozoites of Entamoeba histolytica in fluid aspirated from an abscess, or absence of bacteria and fungi in aspirated fluid and a titer ≥128 in an indirect hemagglutination assay (IHA) for E. histolytica. Of 31 patients with ALA at SNUH from 1990 through 2005, 10 (32%) were HIV positive. The proportion of HIV-infected patients among patients with ALA increased significantly with time (linear-by-linear association, p<0.001) (Figure). Of 10 patients from 1998 through 2005, 8 (80%) were HIV positive. Except for 2 patients with a history of travel to an ALA-endemic area, 88% of the patients were HIV positive.
Figure

Number of cases of amebic liver abscess in patients with and without HIV infection at Seoul National University Hospital, Republic of Korea, 1990–2005.

Number of cases of amebic liver abscess in patients with and without HIV infection at Seoul National University Hospital, Republic of Korea, 1990–2005. Median age of the 10 HIV-positive patients with ALA was 34.5 years (range 29–54 years); all patients were male. Four had a homosexual orientation, 4 had a heterosexual orientation, and 2 had an unknown sexual orientation. Fever (100%) was the most common symptom, and abdominal tenderness (90%) and diarrhea (50%) were frequently observed. Median leukocyte count was 9,000/mm3 (range 3,410–16,700/mm3), and median CD4 cell count was 279/mm3 (range 40–370/mm3). Eight patients had abscesses in the right lobe of the liver and 2 had abscesses in both lobes; 8 patients had 1 abscess and 2 had multiple abscesses. Median size of abscesses was 7.25 cm (range 3–12 cm). In 5 patients, pleural effusion was observed in chest radiographs. IHA titer was ≥128 in 10 patients and ≥512 in 8 patients. Median days to defervescence was 2 (range 1–5 days). In 2 patients, perforation of the abscess into the abdominal cavity was a complication. No patients died or had relapses. Early in the AIDS pandemic, some studies reported that the prevalence of invasive amebiasis was not increased in patients with HIV infection (,). However, recent reports of ALA associated with HIV infection have increased. Studies in Taiwan demonstrated that invasive amebiasis, including ALA, is on the increase in HIV-infected patients in disease- endemic areas (,). Amebiasis was previously an endemic disease in the Republic of Korea. The positive rate for cysts of E. histolytica/E. dispar in the general population was 10% in the 1960s (). However, with improvements in sanitation, this rate decreased to 0.5% in 1993 and to nearly 0% in 2004 (). The present study showed that ALA in association with HIV infection is increasing in the Republic of Korea, and that ALA in HIV-negative patients has greatly decreased. In a study in the United States, 38% of patients with ALA with no history of travel to a disease-endemic area were HIV positive (). These results support the view that ALA is an emerging parasite infection in HIV-infected patients in non–disease-endemic areas, as well as in disease-endemic areas. Immune suppression is an important risk factor for ALA. In animal studies, immune suppression after thymectomy or splenectomy results in an increased incidence of ALA (). Suppressed cellular immunity caused by use of steroids and malnourishment predispose to fatal amebiasis (). In the present study, 90% of patients had CD4 cell counts <350/mm3, which implies that immune suppression by HIV infection may be another risk factor for ALA. Only 2 patients with pyogenic liver abscess were observed during the study. In these patients, pyogenic liver abscess was diagnosed, despite negative cultures for bacteria and fungi, because trophozoites of E. histolytica were not demonstrated in aspirated pus, and results of IHA for amebiasis were negative. However, we cannot exclude amebic liver abscess in these 2 patients because IHA test results can be negative in HIV-infected patients (). This study suggests that ALA is an emerging parasite infection in HIV-infected patients even in areas where the disease is not endemic. ALA should be considered in HIV-infected patients with space-occupying lesions in the liver, and HIV screening is strongly recommended in patients in areas where ALA is not endemic, especially those with no history of travel to a disease-endemic area.
  9 in total

1.  Amoebic liver abscess in HIV-infected patients.

Authors:  M D Oh; K Lee; E Kim; S Lee; N Kim; H Choi; M H Choi; J Y Chai; K Choe
Journal:  AIDS       Date:  2000-08-18       Impact factor: 4.177

2.  Fatal amebiasis complicating corticosteroid management of pemphigus vulgaris.

Authors:  J EISERT; J E HANNIBAL; S L SANDERS
Journal:  N Engl J Med       Date:  1959-10-22       Impact factor: 91.245

3.  Invasive amoebiasis: an emerging parasitic disease in patients infected with HIV in an area endemic for amoebic infection.

Authors:  C C Hung; P J Chen; S M Hsieh; J M Wong; C T Fang; S C Chang; M Y Chen
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

4.  Entamoeba histolytica infection and AIDS.

Authors:  S L Reed; D W Wessel; C E Davis
Journal:  Am J Med       Date:  1991-02       Impact factor: 4.965

5.  Amebic liver abscess and human immunodeficiency virus infection: a report of three cases.

Authors:  C J Liu; C C Hung; M Y Chen; Y P Lai; P J Chen; S H Huang; D S Chen
Journal:  J Clin Gastroenterol       Date:  2001-07       Impact factor: 3.062

6.  The prevalence of invasive amebiasis is not increased in patients with AIDS.

Authors:  J Jessurun; L P Barrón-Rodríguez; G Fernández-Tinoco; M Hernández-Avila
Journal:  AIDS       Date:  1992-03       Impact factor: 4.177

7.  Amebic liver abscess: epidemiology, clinical features, and outcome.

Authors:  R K Seeto; D C Rockey
Journal:  West J Med       Date:  1999-02

8.  Effect of immunosuppression on the size and metastasis of amoebic liver abscesses in hamsters.

Authors:  E Ghadirian; E Meerovitch
Journal:  Parasite Immunol       Date:  1981       Impact factor: 2.280

9.  A note on clinical presentations of amebic liver abscess: an overview from 62 Thai patients.

Authors:  Viroj Wiwanitkit
Journal:  BMC Fam Pract       Date:  2002-07-31       Impact factor: 2.497

  9 in total
  22 in total

1.  The Brief Case: A Rare Case of Invasive Amebiasis Requiring Emergency Subtotal Colectomy in an HIV-Positive Man.

Authors:  Robert Ball; Stephen D Woolley; Fiona Campbell; Tom Wingfield; Richard M Heath; Nick J Beeching; Lance Turtle
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

2.  Asymptomatic intestinal amebiasis in Japanese HIV-1-infected individuals.

Authors:  Koji Watanabe; Naoyoshi Nagata; Katsunori Sekine; Kazuhiro Watanabe; Toru Igari; Junko Tanuma; Yoshimi Kikuchi; Shinichi Oka; Hiroyuki Gatanaga
Journal:  Am J Trop Med Hyg       Date:  2014-07-21       Impact factor: 2.345

3.  Seroprevalence of Entamoeba histolytica infection among men who have sex with men in Sydney, Australia.

Authors:  Rodney James; Joel Barratt; Deborah Marriott; John Harkness; Damien Stark
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

4.  Amebiasis among persons who sought voluntary counseling and testing for human immunodeficiency virus infection: a case-control study.

Authors:  Chien-Ching Hung; Pei-Ying Wu; Sui-Yuan Chang; Dar-Der Ji; Hsin-Yun Sun; Wen-Chun Liu; Cheng-Hsin Wu; Shan-Chwen Chang
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

Review 5.  Advances in sexually transmitted infections of the gastrointestinal tract.

Authors:  Siew C Ng; Brian Gazzard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-25       Impact factor: 46.802

6.  Molecular epidemiology of amebiasis.

Authors:  Ibne Karim M Ali; C Graham Clark; William A Petri
Journal:  Infect Genet Evol       Date:  2008-05-14       Impact factor: 3.342

7.  Cost-effectiveness of detection of intestinal amebiasis by using serology and specific-amebic-antigen assays among persons with or without human immunodeficiency virus infection.

Authors:  Sui-Yuan Chang; Hsin-Yun Sun; Dar-Der Ji; Yi-Chun Lo; Cheng-Hsin Wu; Pei-Ying Wu; Wen-Chun Liu; Chien-Ching Hung; Shan-Chwen Chang
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

8.  Multiple Amoebic Liver Abscess As Initial Manifestation in Hiv Sero-Positive Male.

Authors:  Subrata Chakrabarti
Journal:  J Clin Diagn Res       Date:  2015-06-01

Review 9.  New insights into Entamoeba histolytica pathogenesis.

Authors:  Leigh A Baxt; Upinder Singh
Journal:  Curr Opin Infect Dis       Date:  2008-10       Impact factor: 4.915

10.  Seroprevalence of Entamoeba histolytica infection among Chinese men who have sex with men.

Authors:  Feng Zhou; Mufei Li; Xiangwei Li; Yu Yang; Cong Gao; Qi Jin; Lei Gao
Journal:  PLoS Negl Trop Dis       Date:  2013-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.